Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
-
New narcolepsy drug shows promise in reducing sudden sleep attacks and muscle collapse
Symptom relief CompletedThis study tested a new medicine called ALKS 2680 in 92 adults with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants stopped their usual narcolepsy medications and received either ALKS 2680 or a placebo for …
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New pill aims to keep narcolepsy patients awake during the day
Symptom relief CompletedThis phase 2 study tested an experimental drug called ALKS 2680 in 93 adults with narcolepsy type 2, a condition causing severe daytime sleepiness. Participants took either the drug or a placebo daily to see if it safely improved their ability to stay awake. The trial is now comp…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC